Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) Director Franz B. Humer sold 11,200 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $2.34, for a total value of $26,208.00. Following the completion of the sale, the director now owns 255,253 […]
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Research analysts at William Blair decreased their Q2 2024 EPS estimates for shares of Allogene Therapeutics in a research report issued on Tuesday, May 14th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.39) for the quarter, down from […]
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Analysts tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
Allogene Therapeutics (ALLO) Set to Announce Quarterly Earnings on Monday dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $12.72 Average Target Price from Brokerages themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.